Dominik Richard

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

Naomi Schlesinger, Rieke Alten, Thomas Bardin et al. · Annals of the Rheumatic Diseases · 2012 · 346 citations

Medicine, Pharmacotherapy, Inflammation +16

Canakinumab for the treatment of acute flares in difficult‐to‐treat gouty arthritis: Results of a multicenter, phase II, dose‐ranging study

Alexander So, Marc De Meulemeester, A. Pikhlak et al. · Arthritis & Rheumatism · 2010 · 312 citations

Medicine, Pharmacology, Pharmacotherapy +17

RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Gérald Simonneau, Andrea Maria D’Armini, Peter F. Fedullo et al. · The Lancet Respiratory Medicine · 2017 · 264 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

Naomi Schlesinger, Marc De Meulemeester, A. Pikhlak et al. · Arthritis Research & Therapy · 2011 · 136 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Gérald Simonneau, Andrea Maria D’Armini, Peter F. Fedullo et al. · The Lancet Respiratory Medicine · 2024 · 36 citations

Medicine, Internal Medicine, Pharmacotherapy +11